- Home
- ABUS vs MPB Comparison
ABUS vs MPB Comparison
Compare ABUS & MPB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABUS
- MPB
- Stock Information
- Founded
- ABUS 2005
- MPB 1868
- Country
- ABUS United States
- MPB United States
- Employees
- ABUS N/A
- MPB N/A
- Industry
- ABUS Biotechnology: Pharmaceutical Preparations
- MPB Major Banks
- Sector
- ABUS Health Care
- MPB Finance
- Exchange
- ABUS Nasdaq
- MPB Nasdaq
- Market Cap
- ABUS 711.2M
- MPB 675.9M
- IPO Year
- ABUS N/A
- MPB N/A
- Fundamental
- Price
- ABUS $4.46
- MPB $29.70
- Analyst Decision
- ABUS Strong Buy
- MPB Buy
- Analyst Count
- ABUS 2
- MPB 2
- Target Price
- ABUS $5.00
- MPB $34.50
- AVG Volume (30 Days)
- ABUS 930.7K
- MPB 142.3K
- Earning Date
- ABUS 11-10-2025
- MPB 10-22-2025
- Dividend Yield
- ABUS N/A
- MPB 2.98%
- EPS Growth
- ABUS N/A
- MPB N/A
- EPS
- ABUS N/A
- MPB 2.41
- Revenue
- ABUS $15,416,000.00
- MPB $208,798,000.00
- Revenue This Year
- ABUS $138.02
- MPB $25.28
- Revenue Next Year
- ABUS N/A
- MPB $28.41
- P/E Ratio
- ABUS N/A
- MPB $12.24
- Revenue Growth
- ABUS 53.23
- MPB 20.40
- 52 Week Low
- ABUS $2.71
- MPB $22.50
- 52 Week High
- ABUS $5.10
- MPB $33.87
- Technical
- Relative Strength Index (RSI)
- ABUS 54.42
- MPB 59.71
- Support Level
- ABUS $4.26
- MPB $28.80
- Resistance Level
- ABUS $4.61
- MPB $30.00
- Average True Range (ATR)
- ABUS 0.20
- MPB 0.72
- MACD
- ABUS -0.01
- MPB 0.26
- Stochastic Oscillator
- ABUS 65.45
- MPB 91.28
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
About MPB Mid Penn Bancorp
Mid Penn Bancorp Inc operates in the financial services domain. It conducts commercial banking and trust business in the United States. Its range of services comprises mortgage and home equity loans, secured and unsecured consists and consumer loans, lines of credit, construction financing, farm loans, community development, local government loans, and various types of time and demand deposits.